" class="no-js "lang="en-US"> Curapath Receives GMP Drug Product Manufacturer Accreditation
Friday, March 31, 2023

Breaking News

NEC Establishes Subsidiaries in Europe for Strengthening Global AI Drug Development Business Flare Therapeutics Further Strengthens Leadership Team with Key Executive Appointments and Promotions Sensorion Appoints Khalil Barrage as Interim Chairman of the Board Ablaze Pharmaceuticals Plans Development of Innovative GPC3 Targeted Radiopharmaceutical Therapy for Liver Cancer in Greater China Hansa Biopharma Completes Enrollment in Phase 2 Study of Imlifidase in Guillain-Barré Syndrome (GBS) ProJenX Announces Formation of Scientific Advisory Board for Development of ALS Treatment NADclinic Group, BioStarks and Do Not Age Announce Exclusive Partnership to Revolutionise Personalised Longevity PathAI Announces Collaboration with GSK on NASH Phase 2b Clinical Trial Nanoscope Therapeutics Announces Positive Topline Results from Phase 2b RESTORE Trial of MCO-010 for the Treatment of Retinitis Pigmentosa Glyscend Therapeutics Appoints Biotech Industry Veteran Michael Wyzga to its Board of Directors
Curapath Receives Accreditation as a GMP Investigational Drug Product Manufacturer from the Spanish Agency for Medicine and Health Products | PTF

January 26 2023

Curapath Receives Accreditation as a GMP Investigational Drug Product Manufacturer from the Spanish Agency for Medicine and Health Products

Curapath, a leader in the design, development, and custom manufacturing of polyamino-acid and lipid nanoparticle (LNP) delivery systems for therapeutics and vaccines, today announced the company has received accreditation as a GMP investigational drug product manufacturer from the Spanish Agency for Medicine and Health Products (AEMPS). AEMPS is the regulatory agency that oversees the quality, safety, and efficacy of pharmaceuticals and medical devices in Spain and acts as a representative of the European Medicines Agency (EMA).

“The authorization of manufacturing for clinical drug product from AEMPS is an exciting milestone for our facility in Spain,” said Robert Shaw, Chief Executive Officer of Curapath. “The recognition of our capabilities by this regulatory body means that we can produce drug substance and drug product for our customers’ clinical programs. Importantly, it also provides our customers with the confidence to know Curapath is well positioned to support their future commercial supply requirements.”

This approval builds upon Curapath’s industry-leading expertise in the custom design, development, and production of polymer and lipid-based delivery systems for cell therapy, gene therapy, and vaccines.

  1. NEC Establishes Subsidiaries in Europe for Strengthening Global AI Drug Development Business

    Drug Development

     Read more
  2. Flare Therapeutics Further Strengthens Leadership Team with Key Executive Appointments and Promotions

    Appointments

     Read more
  3. Sensorion Appoints Khalil Barrage as Interim Chairman of the Board

    Appointments

     Read more
  4. Ablaze Pharmaceuticals Plans Development of Innovative GPC3 Targeted Radiopharmaceutical Therapy for Liver Cancer in Greater China

    Diseases

     Read more
  5. Hansa Biopharma Completes Enrollment in Phase 2 Study of Imlifidase in Guillain-Barré Syndrome (GBS)

    Clinical Trials

     Read more
More On